TORONTO, Feb. 23, 2021 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), a specialty
pharmaceutical company focusing on central nervous system and
cardiovascular markets, announces that it will participate in an
upcoming event as part of Renmark Financial Communications Inc.'s
live Virtual Non-Deal Roadshow Series. For this event, Renmark is
focused on attracting participants in the Greater Boston area. Other interested parties
are welcome to attend as well.
- February 25, 2021 at 10:00 AM EST (7:00 AM
PST). To register and attend this live event, please follow
the link:
https://talk-deck.com/info/live-register/?326!ut9dx30v1dy
Gilbert Godin, Chief Executive
Officer, and Tim Hendrickson, Chief
Financial Officer, will deliver the Company's presentation followed
by a live Q&A. Investors interested in participating in the
event will need to register using the link above. As a reminder,
registration for the live event may be limited, but access to the
replay after the event will be on the Company's Investor
website.
To ensure smooth connectivity, please access the link using
the latest version of Google Chrome.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company
focused on the acquisition and commercialization of late-stage
development, commercial stage promoted and established branded
pharmaceutical products in the North American markets. HLS's focus
is on products targeting the central nervous system and
cardiovascular therapeutic areas. HLS's management team is composed
of seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities and expectations regarding financial
performance. The forward-looking events and circumstances discussed
in this release may not occur and could differ materially as a
result of known and unknown risk factors and uncertainties
affecting HLS, including risks relating to the specialty
pharmaceutical industry, risks related to the regulatory approval
process, economic factors and many other factors beyond the control
of HLS. Forward-looking statements and information by their nature
are based on assumptions and involve known and unknown risks,
uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 18, 2020 and Management's
Discussion and Analysis dated November 4,
2020, both of which have been filed on SEDAR and can be
accessed at www.sedar.com. Accordingly, readers should not place
undue reliance on any forward-looking statements or information.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and HLS
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
SOURCE HLS Therapeutics Inc.